Literature DB >> 10500107

Latent reservoirs of HIV: obstacles to the eradication of virus.

T W Chun1, A S Fauci.   

Abstract

The use of highly active antiretroviral therapy (HAART) in the treatment of HIV-1-infected individuals has provided a considerable amount of information regarding the dynamics of viral replication and has resulted in enormous advances in HIV therapeutics. The profound suppression of plasma viremia in HIV-infected individuals receiving HAART has resulted in a highly beneficial clinical effect and a dramatic decrease in the death rate attributable to AIDS. Nonetheless, the persistance of reservoirs of HIV, including latently infected, resting CD4+ T cells that can give rise to infectious HIV upon stimulation in vitro, has posed a sobering challenge to the long-term control or eradication of HIV in infected individuals receiving HAART. Although a recent study has demonstrated th at the size of the pool of latently infected, resting CD4+ T cells can be markedly diminished with intermittent interleukin (IL-2) and continuous HAART, complete eradication of HiV in infected individuals remains extremely problematic. Here we discuss recent developments in studies of the latent reservoir of HIV in patients receiving HAART and implications for the long-term treatment of infected individuals and eradication of the infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500107      PMCID: PMC34225          DOI: 10.1073/pnas.96.20.10958

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease.

Authors:  I Mezzaroma; M Carlesimo; E Pinter; C Alario; G Sacco; D S Muratori; M L Bernardi; R Paganelli; F Aiuti
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

2.  Toward HIV eradication or remission: the tasks ahead.

Authors:  D D Ho
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

3.  A national tissue bank to track HIV eradication and immune reconstruction.

Authors:  W Cavert; A T Haase
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  HIV/AIDS in 1998--gaining the upper hand?

Authors:  O J Cohen; A S Fauci
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

5.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

6.  Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.

Authors:  T W Chun; D Engel; S B Mizell; C W Hallahan; M Fischette; S Park; R T Davey; M Dybul; J A Kovacs; J A Metcalf; J M Mican; M M Berrey; L Corey; H C Lane; A S Fauci
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

Review 7.  A primer on HIV type 1-specific immune function and REMUNE.

Authors:  R B Moss; W K Giermakowska; J R Savary; G Theofan; A E Daigle; S P Richieri; F C Jensen; D J Carlo
Journal:  AIDS Res Hum Retroviruses       Date:  1998-06       Impact factor: 2.205

8.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

Review 9.  Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.

Authors:  L K Schrager; M P D'Souza
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

10.  Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy.

Authors:  S R Lewin; M Vesanen; L Kostrikis; A Hurley; M Duran; L Zhang; D D Ho; M Markowitz
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

View more
  110 in total

1.  Benchmarks for antiretroviral therapy.

Authors:  O J Cohen; A S Fauci
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

Authors:  W S Hlavacek; C Wofsy; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA.

Authors:  N Vandegraaff; R Kumar; C J Burrell; P Li
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

6.  Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Authors:  Frank Wolschendorf; Alexandra Duverger; Jennifer Jones; Frederic H Wagner; Jason Huff; William H Benjamin; Michael S Saag; Michael Niederweis; Olaf Kutsch
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

7.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

9.  Rational design of drugs that induce human immunodeficiency virus replication.

Authors:  Dean H Hamer; Sven Bocklandt; Louise McHugh; Tae-Wook Chun; Peter M Blumberg; Dina M Sigano; Victor E Marquez
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption.

Authors:  Rui Wang; Ante Bing; Cathy Wang; Yuchen Hu; Ronald J Bosch; Victor DeGruttola
Journal:  Stat Med       Date:  2020-04-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.